3+ day, 8+ hour ago   (379+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates in melanoma presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Meredith McKean, MD, MPH: Hi, I am Meredith McKean. I’m a…...

3+ day, 8+ hour ago   (320+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates to Merkel cell carcinoma (MCC) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. McKean describes updates from the STAMP, ADAM, and…...

3+ day, 7+ hour ago   (789+ words) Docwire News Public Policy: How to Get Involved To kick off 2026, Anna Gaddy, MD, of the Nephrology Times editorial board and the Medical College of Wisconsin wanted to explore the role of public policy in nephrology. Following a conversation with…...

3+ day, 8+ hour ago   (553+ words) Roman Bronfenbrener, MD, from Pennsylvania Dermatology Specialists and University of Pennsylvania, discusses some of the key considerations for dermatologists in private practice. Dr Bronfenbrener highlights the importance of financial oversight, saying that financial metrics “should be something that is tracked…...

3+ day, 8+ hour ago   (482+ words) What is the most compelling evidence supporting the use of nocturnal home hemodialysis—particularly for cardiovascular health, volume control, and quality of life? Nocturnal therapy is usually provided four to six times a night with average 5 or 6 to 10 hours for…...

3+ day, 8+ hour ago   (925+ words) Michael Lazarus Award winner Ron Wald, MD,of St. Michael’s Hospital in Toronto, Canada, joined Joel Topf, MD,of Nephrology Times at the 2026 National Kidney Foundation (NKF) Spring Clinical Meetings to discuss dialysis and recent clinical trials. This transcript was…...

3+ day, 8+ hour ago   (290+ words) Jeffrey Hyams, MD, of the University of Connecticut and Connecticut Children’s Hospital in Hartford, Connecticut, shares results from the UNIFI JR trial evaluating ustekinumab in pediatric patients with ulcerative colitis who did not respond to conventional therapies. From these results…...

3+ day, 8+ hour ago   (146+ words) Adam Faye, MD, of NYU Langone Health, New York, New York, shares results from a study evaluating the safety of guselkumab among older populations of patients with immune-mediated inflammatory diseases, such as inflammatory bowel disease (IBD), psoriasis, and psoriatic arthritis....

3+ day, 8+ hour ago   (689+ words) What is the biggest takeaway for clinicians from the CagriSema data presented at the 2026 ADA Scientific Sessions? How does amylin complement GLP-1 therapy, and why is that combination generating so much interest? As natural hormones, the GLP-1 and amylin are…...

3+ day, 8+ hour ago   (427+ words) The following transcript has been edited for clarity. Can you elaborate a little on what the results tell us about survodutide’s unique dual glucagon/GLP-1 mechanism? Dr. Le Roux: Yeah, because survodutide acts like an oxyntomodulin analog, a natural gut…...